Related Experiment Video
Updated: Apr 6, 2026
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Rationale and design of the Corrie Lipids Program: Impact of a digital health-enabled implementation initiative to
Allison W Peng1, Caroline F Plott1, Sohail Zahid1
1Division of Cardiology, Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins School of Medicine, Baltimore, MD.
Insights
The Corrie Lipids Program uses a digital health app and clinician support to improve lipid management in high-risk patients. This initiative aims to increase LDL-C goal achievement and patient engagement in cardiovascular disease care.
Area of Science:
- Digital Health
- Implementation Science
- Cardiovascular Disease Management
Background:
- Atherosclerotic cardiovascular disease (ASCVD) is a leading global cause of death.
- Significant treatment gaps exist in managing low-density lipoprotein cholesterol (LDL-C), including under-prescribing and poor adherence.
- Current interventions struggle to translate evidence-based lipid-lowering therapy (LLT) efficacy into routine clinical practice.
Purpose of the Study:
- To evaluate the Corrie Lipids Program, a digital health initiative designed to address gaps in LLT for ASCVD.
- To increase the proportion of high-risk patients achieving guideline-directed LDL-C goals.
- To improve patient and clinician engagement in lipid management.
Main Methods:
- Prospective, multicenter implementation science study.
- Utilizes a patient-facing smartphone app for tracking, reminders, and education.
- Provides clinicians with virtual coaching, decision support, and workflow integration.
- Evaluates outcomes using the RE-AIM framework; includes qualitative interviews.
Main Results:
- Currently enrolling 124 patients as of March 1, 2026.
- Study initiated in June 2025, with follow-up completion estimated by early 2027.
- No randomization or control group is included in this implementation science study.
Conclusions:
- The Corrie Lipids Program aims to bridge the gap between LLT guidelines and real-world practice.
- Digital health interventions show promise for improving ASCVD risk factor management.
- Further evaluation will determine the program's effectiveness, adoption, implementation, and maintenance.
Rationale:
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of morbidity and mortality worldwide. Lowering low-density lipoprotein cholesterol (LDL-C) with statins and nonstatin therapies has been demonstrated to reduce cardiovascular events. However, real-world evidence consistently reveals large treatment gaps, including underprescribing of lipid-lowering therapy, limited intensification, and poor patient adherence. Observational registries describe these treatment gaps, and randomized trials demonstrate therapy efficacy under controlled conditions, but interventions translating these findings into routine clinical practice remain limited. The Corrie Lipids Program is a digital health initiative designed to address these critical gaps in lipid-lowering as a component of ASCVD treatment by delivering an intervention that combines a patient-facing smartphone app, clinician education and coaching, and seamless incorporation into clinical workflows.
Primary Hypothesis:
The Corrie Lipids Program will increase the proportion of high-risk patients achieving guideline-directed LDL-C goals at 6 and 12 months, and improve both patient and clinician engagement with lipid management through utilizing a digital health platform.
Design:
This is a prospective, multicenter, implementation science study. Participants receive a patient-facing smartphone app with features including lipid tracking, medication reminders, educational content, and engagement tools. Clinicians receive virtual coaching, decision support, and workflow integration to optimize guideline-directed therapy. The study uses the RE-AIM (Reach, Effectiveness, Adoption, Implementation, Maintenance) framework to evaluate effectiveness, adoption, and implementation outcomes. Qualitative interviews with patients and clinicians will explore barriers and facilitators to program adoption. No randomization or control group is included.
Sites:
This study will initially enroll at 3 academic medical centers: Johns Hopkins Medicine, Inova Schar Heart and Vascular, and Penn State Health, with plans for future expansion to additional sites.
Estimated Enrollment:
A total of 1,000 adult patients with uncontrolled LDL-C and at high risk for ASCVD, defined as known or subclinical ASCVD diagnosed by imaging, familial hypercholesterolemia or LDL-C ≥190 mg/dL, diabetes mellitus, individuals who meet criteria for lipid-lowering therapy based on ASCVD risk assessment in the most up-to-date guidelines, or statin-intolerance.
Enrollment Dates:
Initiated in June 2025 with estimated completion of follow-up by early 2027.
Current Status:
Currently enrolling, with 124 patients enrolled as of March 1, 2026.
Trial Registration:
ClinicalTrials.gov Identifier: NCT07478887.
More Related Videos
Related Concept Videos
01:26Atherosclerosis III: Management
01:26Coronary Artery Disease IV: Preventive Measures
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:06Lipid Digestion
01:24Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
01:24Lipid Absorption
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...